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EDITORIAL
The most important questions in cancer 
research and clinical oncology—Question 




Obesity is recognized as the second highest risk factor for cancer. The pathogenic mechanisms underlying tobacco-
related cancers are well characterized and effective programs have led to a decline in smoking and related cancers,  
but there is a global epidemic of obesity without a clear understanding of how obesity causes cancer.  Obesity is 
heterogeneous, and approximately 25% of obese individuals remain healthy (metabolically healthy obese, MHO), so 
which fat deposition (subcutaneous versus visceral, adipose versus ectopic) is “malignant”? What is the mechanism of 
carcinogenesis? Is it by metabolic dysregulation or chronic inflammation? Through which chemokines/genes/signal-
ing pathways does adipose tissue influence carcinogenesis? Can selective inhibition of these pathways uncouple 
obesity from cancers? Do all obesity related cancers (ORCs) share a molecular signature? Are there common (over-
lapping) genetic loci that make individuals susceptible to obesity, metabolic syndrome, and cancers? Can we iden-
tify precursor lesions of ORCs and will early intervention of high risk individuals alter the natural history? It appears 
unlikely that the obesity epidemic will be controlled anytime soon; answers to these questions will help to reduce the 
adverse effect of obesity on human condition.
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Introduction
There is a global obesity pandemic. Obese people get 
more cancers. These are two incontrovertible facts. How-
ever, attempts to clarify the mechanistic links between 
obesity and cancer have raised more questions than 
answers.
Excess body fat is a major global public health prob-
lem. In 2014, the World Health Organization classified 
67% of the population of the United States, 63% of the 
United Kingdom, and 64% of Australia as overweight or 
obese [1]. The global obesity pandemic is not limited to 
Western countries; it also affects “poor countries” such 
as India. Paradoxically, while India is home to the most 
underweight people in the world (202 million) in 2014, 
it also has the fifth highest number of obese men (9.8 
million) and third highest number of obese women (20 
million) [2]. The rate of increase in overweightness and 
obesity appears to have been highest between 1992 and 
2002; although the trend in developed countries has 
slowed over the last decade, it continues to rise in other 
regions of the world [3].
Obesity accounts for approximately 5% of new can-
cers in adults [4], making it the second highest risk fac-
tor. Tobacco exposure is the highest risk factor; however, 
while the biological and natural history of tobacco-
related cancers have been elucidated and effective pre-
ventive programs have been implemented with positive 
results, management of obesity-related cancers (ORCs) 
lags far behind.
The World Cancer Research Fund (WCRF) listed 10 
cancers as obesity-related [4], including post-menopausal 
breast, endometrial, ovarian, advanced prostate, colo-
rectal, renal, pancreatic, liver, and gallbladder cancers, 
as well as esophageal adenocarcinoma. The WCRF esti-
mated that 28% of gallbladder cancers, 35% of pancreatic 
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cancers, and 35% of esophageal cancers are attributable 
to obesity. The International Agency for Research on 
Cancer (IARC) recently released an update on the link 
between obesity and cancer, adding another eight cancers 
(cancers of the gastric cardia, liver, gallbladder, pancreas, 
ovary, and thyroid, as well as meningioma and multiple 
myeloma) to their previous list of five (cancers of the 
colon, esophagus, kidney, breast, and uterus) as having 
sufficient evidence to be called risk factors [5]. Another 
three (prostate cancer, male breast cancer, and diffuse 
large B cell lymphoma) were linked with limited evi-
dence. The IARC did not comment on association versus 
causation.
In the field of adiponcosis, the principal questions that 
need answers are as follows.
Question 1 Cancer and obesity are heterogeneous. 
Which molecular subtypes of cancer are related to or 
caused by “malignant” obesity?
Background
Obesity is heterogeneous [6]. Obesity is not always path-
ogenic; sometimes it is even protective. According to 
Denis and Obin [7] (paraphrasing Tolstoy), lean people 
seem to be mostly alike, whereas obese people are differ-
ent, each in their own way. It seems that both obesity and 
cancer are heterogeneous, raising the question: what is 
“malignant” obesity?
Visceral adipose tissue (VAT), as indicated by central 
obesity, is thought to be pathogenic, whereas subcuta-
neous adipose tissue (SAT) is not [8]. In an interesting 
experiment, colonic adenoma-prone mice were divided 
into three groups—ad libitum fed, visceral fat removed 
with ad  libitum feeding, and visceral fat removed with 
caloric restriction—and then compared. The adenoma 
rate was reduced by the removal of visceral fat but not 
by caloric restriction, indicating an independent effect of 
visceral fat on tumorigenesis [9].
Major studies, including the IARC report, used the 
body mass index (BMI) criteria for defining obesity. 
Although BMI is a good measure of total body fat mass, 
it is an inaccurate measure of clinically relevant obesity. 
VAT is better measured by other parameters, such as 
waist circumference (WC) and waist-to-hip ratio (WHR) 
or by computed tomography (CT) scanning [10]. An 
often quoted article explains how WC, not BMI, explains 
obesity-related health risk [11]. A recent meta-analysis 
suggested that central obesity measured by WC, not by 
WHR, is associated with modestly increased risk of both 
pre- and post-menopausal breast cancer, independent of 
general obesity [12]. More specifically, WHR adjusted for 
BMI appears to give a better measurement of clinically 
relevant obesity [13]. The pitfalls of using such measure-
ments were discussed in a recent review [14]. A caveat 
is that our knowledge of clinically relevant obesity is 
from studies on metabolic syndrome (MetS) and insu-
lin resistance; it is unclear whether ORCs have the same 
etiopathogenesis, and therefore it is unclear if these data 
are applicable. Researchers need to reach consensus on 
a more accurate definition and criteria for “malignant” 
obesity.
It is possible that excess adipose tissue is actually good 
for the body, indicative of adequate storage capacity for 
excess (and potentially lipotoxic) free fatty acid. The 
disease-protective effects of lower body fat have been 
summarized [15]. Surprisingly, the role of VAT as the 
pathogenic fat deposit has not yet been settled. Among 
the components of VAT, mesenteric fat may be more 
important than omental fat in metabolic dysregulation 
[16]. It is possible that the association between metabolic 
dysfunction and visceral obesity could be due to under-
lying processes that predispose to visceral obesity and 
metabolic dysfunction, rather than constituting a direct 
causal relationship [17].
An alternative hypothesis is that lack of adequate stor-
age facility leads to ectopic deposition of fat in the liver 
and skeletal muscle, which causes insulin resistance and 
MetS [18]. Indeed, ectopic liver fat (ELF), which causes 
non-alcoholic fatty liver disease (NAFLD), predicts for 
and appears to be a precursor of MetS [19]. There are 
strong associations between obesity, MetS, and cancers 
[20]. Is it time to shift focus from VAT to ectopic fat as 
the risk factor for ORCs? (Or, in other words, does ELF 
cause ORC?) NAFLD is associated not only with liver 
cancers but also with extra-hepatic cancers [21]. Fatty 
liver releases “hepatokines” such as fetuin-A and FGF21 
with significant roles in carcinogenesis; these roles are 
being investigated [22, 23].
It remains to be determined whether ectopic fat depo-
sition, as measured by fat in the liver or by serum bio-
markers such as alpha-ketoglutarate [24], will provide a 
more accurate measurement of “malignant” fat than VAT. 
Contradictory data exist. Conditions such as lipodystro-
phy, where there is absence of connective tissue fat with 
compensatory NAFLD and insulin resistance, do not 
appear to increase the risk for cancers (Dr. Abhimanyu 
Garg, personal communication). Additionally, African 
Americans are prone to obesity and ORCs but have a 
lower incidence of NAFLD, whereas the reverse is seen 
with Hispanics, who have a higher incidence of NAFLD 
but fewer cancers [25]. Central obesity is a stronger risk 
factor for cancer in Asians than in African Americans 
[26].
Therefore, factors that determine the distribution of fat 
in the deposits are relevant, and this appears to be coded 
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in our genes. Evolutionarily speaking, in people from 
temperate climates, fat is distributed in the subcutane-
ous tissue where it acts as protection against cold (more 
SAT); if fat were distributed in the same way in people 
from tropical regions, it would cause overheating. In pos-
sibly the same way that the camel stores fat in its hump, 
people from tropical regions tend to store fat in the 
abdominal region (more VAT).
Clearly, the pattern of fat distribution is more impor-
tant than the absolute amount of stored fat. Distribution 
of fat over the body is controlled by an array of “fat dis-
tribution genes.” An intriguing possibility is that people 
inherit a pattern of fat distribution genes that makes 
them susceptible, simultaneously, to central obesity and 
cancers; therefore, both fat and cancers are related but 
have independent outcomes. This is in line with current 
ideas on the causes of obesity [27] (Fig.  1). Transcrip-
tional profiling of gluteal and abdominal fat has identified 
an extensive list of differentially expressed developmental 
genes, including members of the homeobox (HOX) fam-
ily, HOX-domain-encoding genes (for example, SHOX2 
and IRX2), and T-box genes (for example, TBX15 and 
TBX5) [28]. These genes are known as transcriptional 
regulators and are involved in early embryonic develop-
ment, body patterning, and cell specification. Interest-
ingly, these genes are also implicated in the oncogenic 
process; that is, “fat distribution genes” are also onco-
genic [29].
A genome-wide association study (GWAS) meta-anal-
yses of traits related to waist and hip circumferences in 
224,459 people identified a list of genes suspected to be 
involved in body fat distribution; these include famil-
iar genes such as SMAD6, BMP2, BCL2, PPARG, and 
VEGFA, which are known to be involved in carcinogen-
esis [30]. Genes such as HOXC8, HOXA5, TBX15, and 
SFRP2 are expressed higher in VAT than SAT, and have 
also been implicated in carcinogenesis [31]. The exact 
relation needs to be further clarified; however, it does 
raise the possibility that both central obesity and ORCs 
are products of an early single event.
Approximately 10%–25% of obese people and a fraction 
of morbidly obese people do not have metabolic distur-
bances [32]. These “metabolically healthy, obese” (MHO) 
people are insulin sensitive and have normal blood 
pressure, a favorable lipid profile, a lower proportion of 
visceral fat, less liver fat, and a normal glucose metabo-
lism, despite having an excessive amount of body fat. At 
the opposite end of the spectrum is a subset of normal 
weight people who suffer from metabolic disturbances 
that are characteristic of obesity (known as “metaboli-
cally obese but normal weight”). Analysis of the Framing-
ham Heart Study of adults who were obese and glucose 
tolerant revealed that potentially MHO people have a 
much lower risk of obesity-associated cancer than those 
who are obese, glucose-intolerant, and potentially “meta-
bolically unhealthy, obese” [33]. The implications are that 
obesity is not a default pro-carcinogenic state and that 
cancers can be uncoupled from obesity.
The brd2-deficient mouse (in which the level of brd2 
gene expression is decreased; total knockout is lethal) 
appears to be a good model to study this possibility [34]. 
This mouse is obese with hyperinsulinemia but is meta-
bolically healthy, appears to be tumor-free, and has a long 
life (up to 20 months). Therapeutic blocking of this gene 
or its pathway could be an option to be obese but healthy.
To add to the complexity, adverse sequelae of obesity 
can be modified by other risk factors, such as ethnicity, 
sex, age at which the person became obese, and especially 
height [35]. Compared with Caucasians at the same BMI, 
South Asians have approximately three times the risk and 
Chinese have approximately twice the risk of developing 
type 2 diabetes [36]. The Framingham Heart Study indi-
cated that being overweight during adolescence may be a 
more significant predictor of colorectal cancer risk than 
being overweight during adulthood [36]. Moreover, the 
association of height with cancer is particularly strong 
Fig. 1 Relation between obesity and cancers: an alternate view
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[35] and is one more reason why BMI is such an unreli-
able measurement of obesity.
Implications: There is an urgent need to better define 
oncogenic fat (SAT vs. VAT vs. ectopic fat) and to meas-
ure it (BMI vs. WC; CT scan vs. biopsy vs. circulating 
markers of NAFLD) to identify a homogenous at-risk 
population that can be targeted for interventions. How-
ever, such criteria should take into account ethnic dif-
ferences [36]. Data from animal studies (brd2-deficient 
mice) and human studies (MHO people) suggest that 
cancer is not an invariable result of obesity and that 
future interventions could uncouple them.
The IARC identified several cancers that are associated 
with obesity [5], but it did not specify which subtype. 
There are many studies on the morphologic subtypes 
associated with obesity [37–41] (representative sample in 
Table 1).
However, the current emphasis is on molecular classifi-
cation of cancers. Which molecular subtype(s) are linked 
to obesity? The new field of molecular pathological epi-
demiology (MPE) may provide some answers [42].
Studies linking obesity to cancer have been performed 
at the genetic and epigenetic levels. At the genetic level, 
alterations in single gene expression and gene pathways 
have been observed, and some molecular signatures have 
been generated. Alterations restricted to single genes 
are rarely reported. Low levels of FASN (the gene for 
fatty acid synthase) are seen in obesity-related colon [43] 
and renal cancers [44]; additionally, a relation has been 
observed in post-menopausal breast cancer with higher 
BMI [45]. FASN is associated with poor prognosis, and 
low levels in ORCs could explain the “obesity paradox” 
[39].
Although tempting, it is unlikely that single gene 
alterations will explain the etiology or identify environ-
mentally derived cancers; differences are more likely to 
lie at least at the pathway level [46]. The data generated 
by various studies linking obesity to molecular subtypes 
are contradictory, possibly related to differing criteria of 
obesity. For example, many studies of colorectal cancer 
did not show consistency on which pathway [the CpG 
island methylator phenotype (CIMP), the chromosomal 
instability (CIN), or the microsomal instability (MSI) 
pathways] is dysregulated. Another study showed that 
obese patients were more likely to be microsatellite sta-
ble (MSS) with a deficient mismatch repair (dMMR) rate 
of 10.3%, which was significantly lower than the dMMR 
rates of 17.1%, 17.4%, and 21.8% in overweight, normal 
weight, and underweight BMI categories, respectively 
[47]. Overall, it appears that, at the molecular level, 
obesity-related colorectal cancer is CIMP-low [48] and 
non-MSI, with altered beta-catenin (CTNNB1) and p53. 
However, findings could vary depending on sex and defi-
nition of obesity (BMI vs. WHR or WC), as shown by the 
Malmö Diet and Cancer Study [49].
The link between obesity and prostate cancer is an 
example of contradictions that occur when all molecular 
subtypes are grouped together. A meta-analysis showed 
that the link between obesity and incidence of pros-
tate cancer is weak [50]. Recent evidence suggested that 
obesity is specifically associated with a reduced risk of 
developing androgen-responsive T2E (TMPRSS2:ERG) 
fusion-positive tumors [51]; this fusion gene is found 
in 50% of prostate cancers, and this could be related to 
lower levels of androgen in obese men. Therefore, linkage 
studies should be specific not only about the type of obe-
sity but also about the molecular subtype of cancer.
One study showed that obesity and physical inactivity 
were associated with a higher risk of CTNNB1-negative 
colorectal cancer [52]. This is consistent with findings in 
studies of the classical endometrioid endometrial cancer 
in obese women, which are usually negative [53]. A recent 
study analyzing The Cancer Genome Atlas (TCGA) data 
concluded that gene expression in endometrial cancer is 
related to BMI [54].
Current research using genomic profiles by techniques 
such as microarrays have generated molecular subtypes 
for most cancers (notably by TCGA). These molecular 
subtypes have been associated with response to treat-
ment and survival (outcomes which are variable and 
strongly influenced by treatment). It is curious that less 
effort has gone into defining subtypes based on etiology 
(which is fixed). Next-generation sequencing technol-
ogy enables us to observe DNA-sequence-level effects of 
well-known mutagens, such as ultraviolet radiation and 
tobacco smoke, as well as endogenous mutagenic pro-
cesses, such as those involving activated DNA cytidine 
deaminases (APOBECs), and generate specific muta-
tion signatures. However, so far, no obesity-associated 
signature has been demonstrated. GWASs conducted 
by multiple consortiums have generated lists of single 
nucleotide polymorphisms (SNPs) associated with obe-
sity. These SNPs were used to produce genetic risk scores 
as a surrogate of “true” (genetic) obesity and then used to 
Table 1 Morphological subtypes of cancers related to obe-
sity
Summarized from references [37–41]
No. Site Morphologic subtype
1. Endometrium Type I-endometroid
2. Colon Left sided
3. Breast Post-menopausal, luminal type, triple negative
4. Kidney Clear cell renal cell cancer
5. Ovary Low grade serous
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link obesity with cancers. The results of these Mendelian 
randomization studies have been usually consistent with 
what we know from epidemiologic studies [38, 55, 56].
Obesity is more likely to alter the epigenome than the 
genome [57]. Diseases including cancers can arise out of 
alterations in the epigenome [58, 59]. Campión et al. [60] 
has identified epigenetically altered genes implicated both 
in obesity and in cancer. Many studies have focused on the 
altered epigenome of obese people in blood cells and adi-
pose tissue [61], normal breast tissue [62], breast cancer 
[63–65], and endometrial precursor lesions and cancer 
[66]. There should be more such epigenome-wide asso-
ciation studies (EWASs) to generate molecular signatures 
across other ORCs and to see if commonality can be identi-
fied across these signatures, irrespective of tissue of origin.
Multiple genomic and epigenomic studies have been 
done with smoking, which is the other major risk fac-
tor for cancer. GWASs have shown gene expression sig-
natures in normal tissue that consistently differentiated 
never-smokers from smokers [67]. It is thought that 
tobacco smoke (like other environmental carcinogens) 
is more likely to alter the epigenome, and EWASs have 
identified molecular signatures specific to tobacco smoke 
[68–71]. Some changes are apparently precursor lesions, 
appearing before the onset of lung cancer [72]. It is not 
unreasonable to expect similar signatures for ORCs.
It would be interesting to know why some organs 
remain free of ORCs. For example, the brain is apparently 
resistant (related to the blood–brain barrier?), and find-
ing the underlying protective mechanism could be useful. 
Other “protected” organs include the rectum, small intes-
tine, urinary bladder, testis, and connective tissue. Lung 
cancer is another, but this could be due to the competing 
stronger risk factor of smoking.
Smoking is known to be associated with cancers devel-
oping at multiple sites, such as the head and neck, lung, 
and bladder [73, 74], but similar data are lacking in 
obese cancer patients. An early study based on Surveil-
lance, Epidemiology, and End Results data suggested that 
multiple primary associations were compatible with the 
existence of common etiologic dietary elements, but this 
study did not specifically look at obesity [75].
Implications: Generating genome/epigenome expres-
sion profiles based on etiology rather than natural history 
will provide a homogenous group of ORCs, which can be 
further studied to clarify the mechanisms of carcinogen-
esis and targets for interventions.
Question 2 Through which factors/genes/signaling 
pathways does adipose tissue influence tumorigenesis?
How does (a specific type of ) obesity cause (a specific 
type of ) cancer? [76].
Some explanations for “adiponcosis” are site-specific—
for example, esophageal adenocarcinomas due to reflux 
and Barret’s esophagus; breast cancer due to raised estro-
gens generated from fatty tissue via aromatase enzyme; 
liver cancer due to NAFLD; and gallbladder cancer due to 
higher incidence of gallstones. A recent study suggested 
that an excess of calories suppress GUCY2C signaling 
(a tumor suppressor gene), resulting in intestinal tumo-
rigenesis in obesity [77, 78]. However, no single unifying 
explanation has been found to be satisfactory.
Dietary components (such as aflatoxin B) can be carci-
nogenic, but such cancers occur irrespective of a person’s 
nutritional state. Unsaturated fatty acids may directly 
alter oncogenic pathways [79]. Direct modification of 
oncogenic pathways by microRNA ingested from milk is 
a postulated mechanism, but whether adequate amounts 
are absorbed is a matter of debate [80].
The two postulated mechanisms by which VAT can 
cause cancer are metabolic dysregulation and chronic 
inflammation [81]. VAT is associated with higher levels 
of insulin and insulin-like growth factor 1 (IGF-1) [82] 
and releases factors involved in metabolic dysregulation, 
such as adipokines (leptin and adiponectin). Major com-
ponents of the inflammation pathway are cytokines such 
as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1-
beta, IL-6, IL-1 receptor antagonist, soluble TNF-alpha 
receptor, and C-reactive protein (the “secretome”) [83]. It 
is also unclear whether the “secretome” has a paracrine 
effect or endocrine. For example, does the fat around the 
breast (SAT) induce breast cancers, or is it an endocrine 
effect of cytokines from VAT? Evidence exists for both 
mechanisms [84–86].
The mitogenic and potentially pro-carcinogenic effects 
of insulin [87] have been hypothesized but unproven for 
decades [88]. The brd2-deficient mouse referred to ear-
lier is obese and hyperinsulinemic but lives tumor-free 
[34]. In contrast, studies in “fatless mice” (A-Zif/F1) sug-
gest that adipokines may not be as important as high lev-
els of insulin, IGF-1, and inflammation, and activation 
of the phosphoinositide 3-kinase (PI3 K)/Akt pathway is 
central to increased cancer risk [89].
The relation between cancer and inflammation has 
been well summarized by Colotta et al. [90]. Up to 40% 
of VAT is composed of infiltrating macrophages that 
are thought to cause a low-grade “chronic inflammatory 
state,” which is pro-carcinogenic. Reactive oxygen and 
nitrogen intermediates are obvious inflammation-gener-
ated candidates causing DNA damage [91]. While there is 
evidence linking inflammation and cancer [92], as seen in 
organ-specific inflammatory disorders such as ulcerative 
colitis, the evidence is weaker for systemic inflammatory 
disorders such as autoimmune diseases. For instance, in 
a large cohort of systemic lupus erythematosus patients, 
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the overall risk of cancer was only marginally increased 
to 14%, and the spectrum was different (significantly only 
for cancers of the vagina and liver and less so for cancers 
of the lung, kidney, and thyroid; cohort members had 
actually lower risks of cancers related to obesity, such as 
breast, uterus, cervix, and prostate cancers) [93]. Indeed, 
chronic syphilis (another inflammatory state) is tradi-
tionally thought to be protective against cancer. Colotto 
et  al. [90] argues that it remains uncertain whether 
chronic inflammation per se´ is sufficient for carcinogen-
esis. A potential candidate is galectin-3, which is secreted 
by macrophages infiltrating adipose tissue. Galectin-3 
is an important regulator of diverse functions that are 
critical in cancer biology, including apoptosis, metastasis, 
immune surveillance, molecular trafficking, mRNA splic-
ing, gene expression, and inflammation, and it has been 
recently identified as a critical factor in insulin resistance 
[94].
Whatever the active components of the malignant 
“secretome” (metabolic vs. inflammatory), it will have to 
act through oncogenic signaling pathways. Those impli-
cated include the phosphatidylinositol 3-kinase/protein 
kinase-B/mammalian target of rapamycin (PI3  K/Akt/
mTOR), the mitogen-activated protein kinase (MAPK), 
the signal transducer and activator of transcription 3 
(STAT3), and the NK-κB pathways. The strongest evi-
dence exists for the PI3K/AKT/mTOR pathway, which is 
the proliferative pathway implicated in many cancers. For 
instance, many of the factors up-regulated in the obesity 
signal via the PI3K pathway. These include leptin, IL-6, 
insulin, TNF, and IGF-1 [95]. PI3K activity is increased 
in diet-induced obesity in mice [96], and tumor growth 
can be abrogated by metformin, which reduced AKT lev-
els [97]. Tumors that are resistant to dietary restriction 
have constitutive activation of the PI3K pathway [98]. 
The evidence for involvement of PI3K pathway in obe-
sity, inflammation and metabolic dysregulation has been 
summarized by Beretta et al. [99].
A couple of issues are worth speculating on. Recent 
studies have shown that obesity can be inherited through 
epigenetic changes that affected the parents (transgen-
erational inheritance of obesity) [100]; this raises the 
question of inheritance of ORCs by similar mechanisms 
[101]. Many cancers have familial clustering but do not 
have a clearly identifiable gene candidate; these are usu-
ally attributed to low-penetrance genes or SNPs. But 
such familial clustering could possibly be due to similar 
epigenetic mechanisms of transgenerational inheritance.
The second issue is, does energy imbalance act early or 
late in carcinogenesis? Carcinogenesis, especially when 
caused by environmental influences, is a multistep pro-
cess, and it would be interesting to know whether obesity 
is the initiator or promoter of cancers.
Implications: It is essential to know which are the 
pathogenic elements of the secretome and through which 
signaling pathway(s) they act. Such information is vital 
from a preventive and therapeutic perspective. The pos-
sibility of transgenerational inheritance of obesity raises 
the possibility that a person could be susceptible to can-
cer just because their parents were obese; more epidemi-
ologic studies need to be oriented towards this link.
Question 3 Are there common (overlapping) genetic 
loci that make individuals susceptible to obesity, meta-
bolic syndrome, and cancers?
In other words, is there a genetic susceptibility to 
obesity, and are these people prone to cancers? Pigeyre 
et  al. [102] summarized the current evidence regarding 
the genetic basis of obesity. Overgrowth syndromes are 
known to have neoplastic susceptibility [103]. Examples 
include WAGR (Wilms tumor), Beckwith-Weidemann 
syndrome (embryonal tumors), and PI3K-related syn-
dromes (multiple tumors). This is consistent with the 
possibility mentioned above that a common genetic fac-
tor could predispose a person to both obesity and cancer.
However, people with polymorphisms of genes such as 
FTO or MC4R, which are associated with risk of obesity, 
have not been found to have a higher risk of colorectal 
[104] or endometrial cancer [105] compared with those 
without these polymorphisms, although a higher risk of 
breast cancer has been noted [106].
Epigenetic factors strongly influence susceptibility to 
obesity. Both intrauterine growth restriction with low 
birth weight, and maternal high-fat diet with high birth 
weight (and, to add to the complexity, low birth weight 
with accelerated catchup growth due to postnatal nutri-
tion) are associated with adult obesity, insulin resist-
ance, metabolic syndrome, NAFLD, and diabetes [107]. 
In sharp contrast to the large amount of data regarding 
metabolic perturbations, scant data exist on whether 
these types of obesity (assuming that different epigenetic 
mechanisms are at work) are associated with increased 
risk of cancer. Mice models suggest that the offspring of 
rat dams that receive a protein-restricted (low protein) 
diet throughout pregnancy and lactation develop mam-
mary tumors more quickly; added nutrition simulating 
accelerated catchup growth increased this risk [108]. 
Consistent with these experimental findings, prenatal 
exposure to starvation increased the risk of breast can-
cer in women of the Dutch Famine cohort [109]; they 
also had higher cancer-related mortality [110]. Data also 
shows that the offspring of mice on a high-fat diet have a 
higher risk of mammary tumors. This is a cause of con-
cern as the ill-effects of the ongoing obesity pandemic 
[111] could be amplified in future generations.
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Not all obese people develop cancers, and not all tis-
sues in obese people are susceptible to ORCs. Cancer 
susceptibility in obese people appears to be strongly 
related to fat distribution (whatever the mechanism), but 
tissue susceptibility to ORCs is a matter of speculation. 
In line with the recent speculation of “bad luck” cancers, 
ORCs have been attributed to increased stem cell prolif-
eration [112, 113] and to differential expression of insulin 
and IGF receptors on tissues [114].
Implications: Identification of genetically and epi-
genetically susceptible “at-risk” individuals is a priority 
for targeted early intervention. It is unclear at this point 
whether these tests will be in the form of genome assays 
or specific serum biomarkers; the ethical implications of 
these tests are unclear as well. The type of intervention 
is also not clear but encouraging data are available on 
drugs such as metformin [115] and on more aggressive 
approaches, such as bariatric surgery, in reducing the risk 
of cancers [116].
Question 4 Are there precursor lesions of ORCs, and 
will their identification help alter the natural history of 
such cancers?
The decline in cardiovascular mortality is due to iden-
tification of early events on the road to potentially fatal 
events, such as myocardial infarction and stroke (such as 
diabetes, hypertension, and hyperlipidemia), and aggres-
sive treatment of the same. Unfortunately, precursor 
lesions (such as ductal carcinoma in situ in breast cancer, 
cervical intraepithelial neoplasia in cervical cancer, and 
polyps in colon cancer) detected during screening proce-
dures need aggressive treatment, which is sometimes as 
morbid as the treatment of established cancer.
Can we detect precursor lesions for ORCs? There are 
tantalizing glimpses of future possibilities. Altered pat-
tern of epigenetic changes occur even before the appear-
ance of cancer. Biopsy of colonic mucosa of healthy 
women showed that methylation in distal mucosa 
increases with higher BMI [117]. Similarly, FASN has 
been shown to be overexpressed in the rectal mucosa of 
obese people, especially men, and has been proposed as 
a marker for colonic neoplasia that is present elsewhere 
[118]. Both “normal” endometrial glands and endo-
metrial complex atypical hyperplasia in obese women 
showed low levels of p27 [119]. Other reported changes 
in precursor lesions include low STMN1 and high KRAS 
expression; KRAS mRNA expression was highly associ-
ated with high BMI [66].
However, the current data have two major limita-
tions. One, the sensitivity, specificity, and reproduc-
ibility of these lesions have yet to be proved relevant 
for clinical use. Two, as shown, a universal precursor 
lesion that is applicable across all tissue types is yet to be 
demonstrated.
It is not possible to biopsy multiple organs-at-risk in 
obese people in the hope of finding precursor lesions. 
It is possible that the developing technology of “liquid 
biopsies” (detection of circulating tumor cells, cell free 
DNA, or exosomes) will prove useful in the future to 
screen for ORCs [120]. However, if precursor lesions are 
to be detected in people at high risk, we need to know the 
specific gene signature identifying precursor lesions of 
ORCs, preferably a universal signature of an ORC-related 
epigenome in circulating healthy or dysplastic epithelial 
cells. Positive liquid biopsies in such individuals would 
be an early warning and set the stage for interventions. 
Altered methylation pattern has been detected in the 
lymphocytes of obese people [121], but more studies are 
needed to identify precursor circulating epithelial cells. 
Several companies, such as Grail (by Illumina), are work-
ing to identify circulating tumor DNA by liquid biopsy as 
a method of screening for early cancer.
Implications: The ideal precursor lesion would (1) be 
detectable in circulating healthy or dysplastic cells on 
“liquid biopsies;” (2) be a molecular signature involv-
ing multiple genes (a single mutation is unlikely to 
explain the link, considering the heterogeneity of issues 
involved); (3) be universal (cutting across tissue types); 
(4) have a possible signature that involves alterations to 
the epigenome; (5) be indicative of pathways involved in 
metabolism and cell proliferation, possibly immunity and 
inflammation; and (6) contain markers for tissue of origin 
to localize the organ-at-risk (to avoid biopsying multiple 
at-risk organs).
As of now, no such biomarker exists; and from a study 
of the literature, there appears to be no effort to find one.
Conclusions
Obesity is believed to be a major cause of cancers. How-
ever, heterogeneity of types of obesity and types of can-
cers, with competing causes, has resulted in a minefield 
of conflicting data. The cause of obesity itself is being 
debated [27]. Accumulating evidence shows that the par-
adigm OBESITY = CANCER is inaccurate.
The obesity pandemic is projected to progress, and 
because of this, ORCs are expected to become more com-
mon [122, 123]. ORCs are a research priority. It is esti-
mated that overweight and obesity accounts for 14% of all 
cancer deaths in men and 20% of those in women [124]. 
Teasing out a homogenous group of cancers that are etio-
logically related at the molecular level (irrespective of 
primary site) is vital; this can be achieved by stricter defi-
nition of obesity in molecular level. We need to improve 
our understanding of how epigenetic events affect a per-
son’s predisposition to obesity and how obesity affects 
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the epigenome [125]. In response to the summoning of 
Chinese Journal of Cancer for collecting key questions in 
cancer research and clinical oncology [126] 4 questions 
are presented here. Future studies are expected to explore 
the following directions:
  • A clearer definition of pathological obesity that can 
be measured easily.
  • Molecular profile of ORCs based on such criteria.
  • Expanded research into the causative mechanism(s).
  • Research into uncoupling obesity from cancer and 
MetS by targeting the responsible genes.
  • Repurposing of drugs currently used in MetS to test 
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